Breaking News Instant updates and real-time market news.

AMZN

Amazon.com

$1,461.76

10.71 (0.74%)

, GOOG

Alphabet

$1,089.52

19.82 (1.85%)

19:20
02/15/18
02/15
19:20
02/15/18
19:20

Amazon, YouTube, Twitter weighing bids for NFL rights, Bloomberg reports

Amazon (AMZN), Google's (GOOG) YouTube, and Twitter (TWTR) are all mulling bids for streaming rights to the NFL's "Thursday Night Football" programming, Bloomberg reports, citing people with knowledge of the matter. The three companies are offering as much as hundreds of millions of dollars for rights that will run for as long as five years, the report says. The NFL is receiving help in discussions on the matter from 21st Century Fox (FOXA), which acquire the TV rights to the games through 2022, the report says.

AMZN

Amazon.com

$1,461.76

10.71 (0.74%)

GOOG

Alphabet

$1,089.52

19.82 (1.85%)

GOOGL

Alphabet Class A

$1,091.36

18.66 (1.74%)

TWTR

Twitter

$33.61

-0.14 (-0.41%)

FOX

21st Century Fox

$36.65

0.47 (1.30%)

FOXA

21st Century Fox

$36.96

0.41 (1.12%)

  • 23

    Feb

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 01

    Mar

  • 05

    Mar

  • 07

    Mar

  • 18

    Mar

AMZN Amazon.com
$1,461.76

10.71 (0.74%)

02/14/18
JEFF
02/14/18
NO CHANGE
JEFF
Amazon focusing on bolstering medical device distribution, says Jefferies
Yesterday's Wall Street Journal report and a recent scan of job postings still point to Amazon.com's (AMZN) focus on bolstering its medical device/supplies distribution capabilities, specifically targeting hospitals, Jefferies analyst Brian Tanquilut. These postings support a negative thesis for Cardinal Health (CAH), Owens & Minor (OMI) and Premier's (PINC) medical supplies businesses, the analyst adds. Further, he sees the news as an incremental positive for AmerisourceBergen (ABC), McKesson (MCK), CVS Health (CVS) and Walgreens Boots Alliance (WBA) since it further supports the view that Amazon isn't looking to enter the prescription business near-term.
02/14/18
BARD
02/14/18
NO CHANGE
Target $9
BARD
Neutral
ChannelAdvisor outlook likely to weigh on sentiment, says Baird
Baird analyst Colin Sebastian noted ChannelAdvisor (ECOM) missed Q4 estimates and cited non-core marketplace struggles as the cause. The analyst was positive on the company's improved performance across both the eBay (EBAY) and Amazon (AMZN) channels and is a positive for growth. Sebastian considers ChannelAdvisor a "show-me" story and maintained his Neutral rating while lowering his price target to $9 from $10 on the shares.
02/15/18
SBSH
02/15/18
NO CHANGE
Target $96
SBSH
Buy
TJX concerns brings buying opportunity, says Citi
Citi analyst Paul Lejuez says sentiment has turned cautious on TJX (TJX) following the company's weak Q3 comp. The stock has underperformed most Specialty Softlines peers over the past three months and the multiple gap with Ross Stores (ROST) is now the widest it has been in 10 years, Lejuez tells investors in a research note. He believes the concerns weighing on TJX shares presents a buying opportunity. The analyst feels the company can quickly fix the fashion miss that dragged Marmaxx's comp down in Q3. He points out that the company has been winning market share along with Amazon.com (AMZN). It's the weaker players, like mall-based department stores, that are losing to Amazon, Lejuez argues. He keeps a Buy rating on TJX with a $96 price target.
02/15/18
BERN
02/15/18
NO CHANGE
BERN
Walgreens/AmerisourceBergen deal a reaction to potential Amazon disruption, says Bernstein
Bernstein analyst Lance Wilkes sees a potential Walgreens (WBA)/AmerisourceBergen (ABC) deal as being a strategic reaction to gross margin pressures and potential disruption from Amazon (AMZN). His initial view is neutral to this deal, as he does not see it as strategically attractive, given his long-term concerns on the distributor role given his expectation of Amazon disruption to retail pharmacy. Wilkes would expect near-term synergies to be more limited, given the existing relationships between the companies and Walgreens's attractive economics already being achieved through the generic consortium.
GOOG Alphabet
$1,089.52

19.82 (1.85%)

02/15/18
MSCO
02/15/18
NO CHANGE
Target $28
MSCO
Underweight
Twitter price target raised to $28 from $15 at Morgan Stanley
Morgan Stanley analyst Brian Nowak said he underestimated Twitter's (TWTR) turnaround efforts throughout 2017 and he has raised his price target on the stock to $28 from $15 given the company's better revenue outlook and high incremental margins. However, despite Twitter's better than expected results, he still sees the stock being a relative underperformer from current levels when compared to faster growing peers like Facebook (FB) and Alphabet (GOOGL), he tells investors. Nowak keeps an Underweight rating on Twitter.
02/02/18
02/02/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apple (AAPL) was downgraded to Market Perform from Outperform at Bernstein and to Sector Weight from Overweight at KeyBanc. 2. Alphabet (GOOG, GOOGL) downgraded to Hold from Buy at Stifel with analyst Scott Devitt citing fourth quarter results and saying he has some longer-term concerns around competition from Amazon (AMZN), Google Cloud Platform market share, regulatory risk and rising traffic acquisition cost. 3. Hershey (HSY) downgraded to Neutral from Outperform at Credit Suisse with analyst Robert Moskow saying the stock deserves a "more narrow" valuation premium to food peers than in the past due to the deceleration of its growth rate and the stagnation of its profit margin. 4. Impinj (PI) was downgraded to Neutral from Buy at Dougherty, to Hold from Buy at Needham and Canaccord, and to Sector Perform from Outperform at RBC Capital. 5. Tractor Supply (TSCO) downgraded to Underperform from Buy at BofA/Merrill with analyst Elizabeth Suzuki saying the fourth quarter results were strong, but the outlook for 2018 was disappointing as management outlined expectations for operating margin compression and a store growth trajectory. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/02/18
FBCO
02/02/18
NO CHANGE
Target $1400
FBCO
Outperform
Alphabet price target raised to $1,400 from $1,350 at Credit Suisse
Credit Suisse analyst Stephen Ju attributes greater than expected marketing spending to promote growth in hardware, cloud, and YouTube as driving the shortfall in Alphabet's operating profit compared to estimates, though he said investors should be "happy to underwrite the incremental marketing and capex" spending in pursuit of the longer-term opportunity. As bright spots in the quarter, Ju points to the company's disclosure that Google's Cloud business is now at a $1B per quarter run rate and likely growing well in the triple-digit range and the fact that device shipments in the hardware business are also growing over 100%. Ju raised his price target to $1,400 and keeps an Outperform rating on Alphabet shares.
02/06/18
CHLM
02/06/18
NO CHANGE
Target $80
CHLM
Buy
Craig-Hallum remains a buyer of Nutrisystem as Google trends continue to lag
Craig-Hallum analyst Alex Fuhrman says Nutrisystem (NTRI) Google (GOOG; GOOGL) trends continue to lag, setting up a buying opportunity despite mixed indicators. Mixed indicators suggest the Nutrisystem brand is not likely to accelerate revenue growth in 2018 from 2017's 23% levels, however the analyst believes there is still strong potential to exceed his estimate of about 11% growth for the brand in 2018. He reiterates a Buy rating and $80 price target on Nutrisystem's shares.
GOOGL Alphabet Class A
$1,091.36

18.66 (1.74%)

02/05/18
ARGS
02/05/18
NO CHANGE
Target $1300
ARGS
Buy
Alphabet price target raised to $1,300 from $1,220 at Argus
Argus analyst Joseph Bonner raised his price target on Alphabet to $1,300, citing strong growth in mobile search as well as "significant revenue growth" from the company's next-generation businesses - YouTube, Google Cloud, and Google Play. The analyst contends that Alphabet is navigating the desktop-to-mobile paradigm shift successfully while adding that the stock valuation is attractive against the backdrop of rapidly expanding business.
TWTR Twitter
$33.61

-0.14 (-0.41%)

02/12/18
BMOC
02/12/18
NO CHANGE
Target $28
BMOC
Market Perform
Twitter price target raised to $28 from $22 at BMO Capital
BMO Capital analyst Daniel Salmon raised his price target on Twitter (TWTR) to $28 after Q1 results, saying the company has a "clearer strategy" to sustain its revenue momentum thanks to video and AI helping grow mainstream adoption. As top-line pressures fade, writes the analyst in his research note titled "Solid Steps Down Road to Recovery", the stock could become "more interesting", though he is also weary of Facebook (FB) competition still "looming large". Salmon keeps a Market Perform rating on Twitter.
02/09/18
02/09/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Twitter (TWTR) upgraded to Sector Perform from Underperform at RBC Capital with analyst Mark Mahaney saying the fourth quarter revenue and EBITDA were materially better than expected, and while MAU's were below consensus, DAU's grew for the first time at a double-digit rate. 2. iRobot (IRBT) upgraded to Outperform from Market Perform at Raymond James with analyst Mark Strouse saying he sees a more balanced risk/reward following the recent pullback in the shares. 3. Regeneron (REGN) upgraded to Outperform from Neutral at Baird with analyst Brian Skorney noting its selloff since last year and believes its valuation has reached a point where the selloff is overdone. 4. Teva (TEVA) upgraded to Sector Perform from Underperform at RBC Capital with analyst Randall Stanicky saying the 11% sell-off in the stock price following the company's guidance update has removed the debate around 2018 EBITDA target and sees limited downside from the current levels. 5. United Technologies (UTX) upgraded to Buy from Hold at Argus with analyst John Eade saying the company remains a leader in a number of global industries and should continue to benefit from population growth and middle class expansion in developing markets. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/09/18
RHCO
02/09/18
NO CHANGE
Target $29
RHCO
Hold
Twitter price target raised to $29 from $18 at SunTrust
SunTrust analyst Youssef Squali raised his price target on Twitter to $29 after improved monetization seen in the company's Q4 earnings, but says the flat MAU's and high valuation keeps his rating on Hold. Squali points to "growing user engagement and better cost containment leading to record high margins and free cash flow" and believes the momentum is likely sustainable as Twitter management improves the product and the ad platform to attract larger advertisers.
FOX 21st Century Fox
$36.65

0.47 (1.30%)

01/28/18
PIPR
01/28/18
NO CHANGE
PIPR
Growth of sports rights may be coming down, says Piper Jaffray
Piper Jaffray analyst Stan Meyers says he is starting to see some evidence that the growth of sports rights may be coming down toward a more reasonable rate. The analyst notes that only CBS (CBS), Fox (FOXA) and NBC (CMCSK; CMCSA) submitted bids for Thursday Night Football rights, with CBS and NBC submitting bids below their current rate of $450M per year, and Fox making a higher bid for the rights, in a likely effort to establish itself as a "live sports and news" network in the wake of selling a majority of assets to Disney (DIS). On the digital side, Facebook (FB) declined to make an offer for digital streaming rights to TNF, while Amazon (AMZN), which paid $50M this year, and Twitter (TWTR), which paid $10M last year did submit bids.
12/18/17
UBSW
12/18/17
NO CHANGE
Target $122
UBSW
Buy
Disney deal for Fox fits both strategically and financially, says UBS
UBS analyst John Hodulik said Disney's (DIS) deal for Fox (FOXA) strengthens its asset base amid the evolving media landscape and fits well both strategically and financially. He believes the deal enhances Disney's growth trajectory and will be accretive to 2020 free cash flow while helping it widen its appeal and target audience. Hodulik reiterated his Buy rating and $122 price target on Disney shares.
12/13/17
BTIG
12/13/17
NO CHANGE
BTIG
Disney, Fox deal may be a near-term positive for Netflix, BTIG says
Commenting on Disney's (DIS) deal with Fox (FOX; FOXA) and its potential implications, BTIG's Richard Greenfield notes that the knee jerk reaction he hears across the investment world is the former is buying the later to build their "Netflix killer." Greenfield "strongly disagrees" with this viewpoint, saying that if Disney wanted to build a Netflix competitor it should be eliminating its stock buyback and aggressively investing in content that has no legacy media strings attached. Further, the Disney/Fox transaction is likely a near-to-intermediate term positive for Netflix, he argues, adding that both companies will be tied up in a 12 month or more regulatory review process with thousands of executives in limbo pending the closing of the transaction.
12/13/17
FBNS
12/13/17
NO CHANGE
FBNS
FBN says Fox could be worth over $42 per share with Disney deal
With multiple media report indicating that Disney (DIS) is close to finalizing a deal to buy most of 21st Century Fox's (FOX) assets and operations, FBN Securities analyst Robert Routh is estimating that Fox shares could have a "real value" of $42.46 based on what has been reported on the likely deal. This estimate is before considering taxes and taking into account that Disney shares will likely rise after a deal is confirmed, said Routh, who does not officially cover either Disney or Fox.
FOXA 21st Century Fox
$36.96

0.41 (1.12%)

01/22/18
ATLE
01/22/18
UPGRADE
ATLE
Overweight
21st Century Fox upgraded to Overweight from Neutral at Atlantic Equities
01/16/18
RILY
01/16/18
UPGRADE
Target $46
RILY
Buy
21st Century Fox upgraded to Buy from Neutral at B. Riley FBR
B. Riley FBR analyst Barton Crockett upgraded 21st Century Fox to Buy and raised his price target for the shares to $46 from $38. The analyst raised his estimates and price targets across the entire media sector reflect the benefits of tax reform.
01/10/18
BOFA
01/10/18
NO CHANGE
Target $144
BOFA
Buy
Disney price target raised to $144 from $130 at BofA/Merrill
BofA/Merrill analyst Jessica Reif Cohen raised her price target for Disney (DIS) to $144 from $130 as she believes it offers a "solid" catalyst pipeline for upside potential in 2018/2019, driven by a strong film release slate, a potential spring analyst event to discuss direct-to-consumer strategy, the opening of Toy Story Land, DTC/Hulu, and accelerating buybacks ahead of its pending 21st Century Fox (FOXA) acquisition. The analyst also projects Disney's Q1 will reflect healthy Studio and Theme Park trends, partially offset by unfavorable comps at Consumer Products and ratings headwinds/streaming investments Media Networks. Cohen reiterates a Buy rating on Disney's shares.

TODAY'S FREE FLY STORIES

RHHBY

Roche

$0.00

(0.00%)

05:24
12/10/18
12/10
05:24
12/10/18
05:24
Hot Stocks
Roche CEO Daniel O'Day to step down, Genentech CEO William Anderson to succeed »

Roche (RHHBY) announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 24

    Dec

  • 18

    Mar

EA

Electronic Arts

$82.57

-1.29 (-1.54%)

05:22
12/10/18
12/10
05:22
12/10/18
05:22
Recommendations
Electronic Arts analyst commentary  »

Electronic Arts price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GILD

Gilead

$68.17

-2.01 (-2.86%)

, RHHBY

Roche

$0.00

(0.00%)

05:21
12/10/18
12/10
05:21
12/10/18
05:21
Hot Stocks
Gilead appoints Roche CEO Daniel O'Day as CEO, chairman »

Gilead Sciences announced…

GILD

Gilead

$68.17

-2.01 (-2.86%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 24

    Dec

  • 18

    Mar

FIVE

Five Below

$95.53

-6.19 (-6.09%)

05:16
12/10/18
12/10
05:16
12/10/18
05:16
Upgrade
Five Below rating change  »

Five Below upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMXAY

Genmab

$0.00

(0.00%)

05:12
12/10/18
12/10
05:12
12/10/18
05:12
Upgrade
Genmab rating change  »

Genmab upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UCBJY

UCB

$0.00

(0.00%)

05:10
12/10/18
12/10
05:10
12/10/18
05:10
Upgrade
UCB rating change  »

UCB upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWTUY

Swedish Orphan Biovitrum

$0.00

(0.00%)

05:08
12/10/18
12/10
05:08
12/10/18
05:08
Upgrade
Swedish Orphan Biovitrum rating change  »

Swedish Orphan Biovitrum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOR

MorphoSys

$27.63

-0.105 (-0.38%)

, JNJ

Johnson & Johnson

$145.38

-0.52 (-0.36%)

05:06
12/10/18
12/10
05:06
12/10/18
05:06
Upgrade
MorphoSys, Johnson & Johnson rating change  »

MorphoSys upgraded to Buy…

MOR

MorphoSys

$27.63

-0.105 (-0.38%)

JNJ

Johnson & Johnson

$145.38

-0.52 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

SLG

SL Green Realty

$93.32

-2.41 (-2.52%)

05:02
12/10/18
12/10
05:02
12/10/18
05:02
Upgrade
SL Green Realty rating change  »

SL Green Realty upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMA

Comerica

$74.07

-1.04 (-1.38%)

04:59
12/10/18
12/10
04:59
12/10/18
04:59
Downgrade
Comerica rating change  »

Comerica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

PII

Polaris Industries

$88.44

-2.37 (-2.61%)

04:58
12/10/18
12/10
04:58
12/10/18
04:58
Downgrade
Polaris Industries rating change  »

Polaris Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

MPX

Marine Products

$21.59

-0.21 (-0.96%)

04:56
12/10/18
12/10
04:56
12/10/18
04:56
Downgrade
Marine Products rating change  »

Marine Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VC

Visteon

$67.58

-4.1 (-5.72%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Downgrade
Visteon rating change  »

Visteon downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CORT

Corcept Therapeutics

$13.06

0.01 (0.08%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
Corcept Therapeutics management to meet with B.Riley FBR »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

BRG

Bluerock Residential

$9.55

-0.22 (-2.25%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
Bluerock Residential management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

GRUB

GrubHub

$76.80

-4.57 (-5.62%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
GrubHub management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 14

    Dec

HWC

Hancock Whitney

$38.24

0.25 (0.66%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
Hancock Whitney management to meet with Sandler O'Neill »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

KMPR

Kemper

$69.81

-2 (-2.79%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
Kemper management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

NBGIF

National Bank of Greece

$0.00

(0.00%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
National Bank of Greece management to meet with Morgan Stanley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

RESI

Front Yard Residential

$9.69

(0.00%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
Front Yard Residential management to meet with JMP Securities »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

PETQ

PetIQ

$31.46

0.09 (0.29%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
PetIQ management to meet with William Blair »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

AMAG

Amag Pharmaceuticals

$17.53

-0.58 (-3.20%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
Amag Pharmaceuticals management to meet with Leerink »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

  • 23

    Mar

ATO

Atmos Energy

$98.80

0.26 (0.26%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
Atmos Energy management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

BC

Brunswick

$49.58

-1.56 (-3.05%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
Brunswick management to meet with KeyBanc »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

CMCO

Columbus McKinnon

$31.52

-0.88 (-2.72%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
Columbus McKinnon management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.